Gilead Sciences (GILD) Competitors

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Is GILD or AMGN a better dividend stock?

Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.8%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 62.9% of its earnings in the form of a dividend. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 10 consecutive years and Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Do insiders & institutionals believe in GILD or AMGN?

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 0.8% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has preferable valuation and earnings, GILD or AMGN?

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$28.75B	4.86	$480M	$5.02	22.45
Amgen	$33.42B	4.80	$4.09B	$12.23	24.36

Do analysts rate GILD or AMGN?

Gilead Sciences currently has a consensus price target of $117.17, suggesting a potential upside of 3.97%. Amgen has a consensus price target of $309.70, suggesting a potential upside of 3.96%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Gilead Sciences is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	6 Hold rating(s)	20 Buy rating(s)	3 Strong Buy rating(s)	2.90
Amgen	1 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.29

Does the media refer more to GILD or AMGN?

In the previous week, Amgen had 1 more articles in the media than Gilead Sciences. MarketBeat recorded 54 mentions for Amgen and 53 mentions for Gilead Sciences. Amgen's average media sentiment score of 1.39 beat Gilead Sciences' score of 1.39 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	46 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	47 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, GILD or AMGN?

Gilead Sciences has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Is GILD or AMGN more profitable?

Gilead Sciences has a net margin of 21.86% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	21.86%	50.99%	17.24%
Amgen	18.96%	174.71%	13.12%

Summary

Amgen beats Gilead Sciences on 11 of the 20 factors compared between the two stocks.